3M will spin off its health care business into a new public company

A 3M logo is seen atop a Versaflo TR-300+ powered air purifying respirator hood as Nurse Evan Brost puts on personal protective equipment (PPE) before entering a patient room in a wing housing coronavirus disease (COVID-19) patients at UW Health University Hospital in Madison, Wisconsin, U.S. November 18, 2020.

Daniel Acker | Reuters

3M announced Tuesday that it will spin off its health care business into a separate publicly traded company.

The new business will focus on wound and oral care, healthcare IT and biopharma filtration, the material science company said in a release.

The announcement comes as 3M spins off another company focusing on food safety, a process which is scheduled to be completed by September.

This is breaking news. Please check back for updates.

Source

Health

Pfizer tops estimates, raises profit guidance even as sales fall

November 4, 2025

Smith Collection | Archive Photos | Getty Images Pfizer on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit guidance, as cost cuts helped to outweigh declining sales for the period. The pharmaceutical giant now expects its full-year adjusted profit to come in between $3 and $3.15 per share, up […]

Health

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

November 3, 2025

A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025. Mike Blake | Reuters Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker’s attempt to outbid Pfizer to acquire the obesity biotech is […]

Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

October 30, 2025

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]